Erlotinib Unknown Status Phase 2 Trials for Lung Cancer Non-Small Cell Cancer (NSCLC) Diagnostic

IndicationsStatusPurposePhase
Unknown StatusDiagnostic2
clinicaltrials.gov IdentifierTitleDrugs
NCT00568841Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)